Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
EDN1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| OXYGEN THERAPY | ? unclear | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| TAMOXIFEN | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| THIOURACIL | ? unclear | Mechanistic | DGIdb | |
| ALPROSTADIL | ? unclear | Mechanistic | DGIdb | |
| ANTIPLATELET AGENT | ? unclear | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| BUDESONIDE | ? unclear | Mechanistic | DGIdb | |
| LANREOTIDE ACETATE | ? unclear | Mechanistic | DGIdb | |
| CANDESARTAN CILEXETIL | ? unclear | Mechanistic | DGIdb | |
| ANESTHETIC AGENT | ? unclear | Mechanistic | DGIdb | |
| BEVACIZUMAB | ? unclear | Mechanistic | DGIdb | |
| PROTEIN SYNTHESIS INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| DEFEROXAMINE | ? unclear | Mechanistic | DGIdb | |
| NORETHINDRONE ACETATE | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| MURAGLITAZAR | ? unclear | Mechanistic | DGIdb |
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DESIRUDIN | ↓ inhibits | Mechanistic | DGIdb | |
| BIVALIRUDIN | ↓ inhibits | Mechanistic | DGIdb | |
| TAMOXIFEN | ? unclear | Mechanistic | DGIdb | |
| PEGMUSIRUDIN | ? unclear | Mechanistic | DGIdb | |
| FLOVAGATRAN | ? unclear | Mechanistic | DGIdb | |
| ANISINDIONE | ? unclear | Mechanistic | DGIdb | |
| HEPARIN | ? unclear | Mechanistic | DGIdb | |
| CATECHIN | ? unclear | Mechanistic | DGIdb | |
| DABIGATRAN | ↓ inhibits | Mechanistic | DGIdb | |
| DABIGATRAN ETEXILATE MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| QUERCETIN | ? unclear | Mechanistic | DGIdb | |
| ODIPARCIL | ? unclear | Mechanistic | DGIdb | |
| DPOC-4088 | ? unclear | Mechanistic | DGIdb | |
| LUSUTROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| ICHORCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PYRIDOXAL PHOSPHATE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| BORTEZOMIB | ? unclear | Mechanistic | 13000.0 nM (Ki) | DGIdb |
| ANTITHROMBIN ALFA | ↓ inhibits | Mechanistic | DGIdb | |
| SR-123781A | ? unclear | Mechanistic | DGIdb | |
| ENOXAPARIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| CYANIDIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL586628 | ? unclear | Mechanistic | DGIdb | |
| AZD-8165 | ? unclear | Mechanistic | DGIdb | |
| STAUROSPORINE | ↓ inhibits | Mechanistic | DGIdb | |
| AVATROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| HIRUDIN | ? unclear | Mechanistic | DGIdb | |
| CYANIN | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 2C [PMID: 24900538] | ↓ inhibits | Mechanistic | DGIdb | |
| SILIBININ | ? unclear | Mechanistic | DGIdb | |
| EP-217609 | ? unclear | Mechanistic | DGIdb | |
| APRAMIDE A | ? unclear | Mechanistic | DGIdb | |
| EPICATECHIN | ? unclear | Mechanistic | DGIdb | |
| ARGATROBAN | ↓ inhibits | Mechanistic | DGIdb | |
| MELAGATRAN | ? unclear | Mechanistic | 4700.0 nM (IC50) | DGIdb |
| ATECEGATRAN METOXIL | ↓ inhibits | Mechanistic | DGIdb | |
| ASPIRIN TRELAMINE | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K3 | ? unclear | Mechanistic | DGIdb | |
| XIMELAGATRAN | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1083499 | ? unclear | Mechanistic | DGIdb | |
| DABIGATRAN ETEXILATE | ? unclear | Mechanistic | Open Targets |
Showing top 40 of 238 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ~ modulates | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| PF-04236921 | ↓ inhibits | Mechanistic | DGIdb | |
| MRA 003 US | ↓ inhibits | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| SILTUXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| DULOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MEDI-5117 | ↓ inhibits | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| BIAFINE CREAM | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ? unclear | Mechanistic | DGIdb | |
| ELSILIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA PREPARATION | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| FENOFIBRATE MICRONIZED | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| RIBAVIRIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| ARSENIC TRIOXIDE | ? unclear | Mechanistic | DGIdb | |
| DIHYDROSPHINGOSINE | ? unclear | Mechanistic | DGIdb | |
| LEVOFLOXACIN ANHYDROUS | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 173 agents ranked by evidence tier.
LDLR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| GLUCAGON (RDNA) | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A | ? unclear | Mechanistic | DGIdb | |
| COLESTIPOL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| HEPARIN CALCIUM | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL233611 | ? unclear | Mechanistic | DGIdb | |
| TRIBUTYRIN | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT TRANSFORMING GROWTH FACTOR | ? unclear | Mechanistic | DGIdb | |
| CHOLESTYRAMINE RESIN | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| EPOETIN ALFA | ? unclear | Mechanistic | DGIdb | |
| TETRACYCLINE | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL DECANOATE | ? unclear | Mechanistic | DGIdb | |
| MIPOMERSEN | ? unclear | Mechanistic | DGIdb | |
| PHYTOESTROGEN | ? unclear | Mechanistic | DGIdb | |
| ANTIVIRAL AGENT | ? unclear | Mechanistic | DGIdb | |
| FAT EMULSION | ? unclear | Mechanistic | DGIdb | |
| VERAPAMIL | ? unclear | Mechanistic | DGIdb | |
| LOMITAPIDE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| SOY PROTEIN ISOLATE | ? unclear | Mechanistic | DGIdb | |
| ANTIBIOTIC | ? unclear | Mechanistic | DGIdb | |
| BUTYRIC ACID | ? unclear | Mechanistic | DGIdb | |
| ACTH | ? unclear | Mechanistic | DGIdb | |
| ALIROCUMAB | ? unclear | Mechanistic | DGIdb | |
| INCLISIRAN | ? unclear | Mechanistic | DGIdb | |
| LOVASTATIN | ? unclear | Mechanistic | DGIdb | |
| ACETYLCYSTEINE | ? unclear | Mechanistic | DGIdb | |
| ROSUVASTATIN | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| EVINACUMAB | ? unclear | Mechanistic | DGIdb | |
| CHEMBL114890 | ↑ activates | Mechanistic | 700.0 nM (EC50) | ChEMBL |
| CHEMBL114705 | ↑ activates | Mechanistic | 1200.0 nM (EC50) | ChEMBL |
| CHEMBL115304 | ↑ activates | Mechanistic | 1300.0 nM (EC50) | ChEMBL |
| CHEMBL324616 | ↑ activates | Mechanistic | 700.0 nM (EC50) | ChEMBL |
| CHEMBL115205 | ↑ activates | Mechanistic | 4000.0 nM (EC50) | ChEMBL |
| CHEMBL112449 | ↑ activates | Mechanistic | 1000.0 nM (EC50) | ChEMBL |
| CHEMBL419400 | ↑ activates | Mechanistic | 7000.0 nM (EC50) | ChEMBL |
| CHEMBL419763 | ↑ activates | Mechanistic | 1700.0 nM (EC50) | ChEMBL |
| CHEMBL419042 | ↑ activates | Mechanistic | 2000.0 nM (EC50) | ChEMBL |
Showing top 40 of 48 agents ranked by evidence tier.
NOS3
Pipeline results not yet available for this target. Run the pipeline to populate.
PCSK9
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ALIROCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| ONGERICIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TAFOLECIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LOMITAPIDE MESYLATE | ? unclear | Mechanistic | DGIdb | |
| EVOLOCUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| RG-7652 | ↓ inhibits | Mechanistic | DGIdb | |
| BOCOCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| FROVOCIMAB | ? unclear | Mechanistic | DGIdb | |
| RALPANCIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LERODALCIBEP | ↓ inhibits | Mechanistic | DGIdb | |
| INCLISIRAN | ? unclear | Mechanistic | DGIdb | |
| INCLISIRAN SODIUM | ? unclear | Mechanistic | Open Targets | |
| DIPHENYL BORINIC ACID | ↓ inhibits | Mechanistic | 30000.0 nM (Ki) | ChEMBL |
| PHENYL BUTYL BORINIC ACID | ↓ inhibits | Mechanistic | 1000.0 nM (Ki) | ChEMBL |
| CHEMBL4107804 | ↓ inhibits | Mechanistic | 3200.0 nM (IC50) | ChEMBL |
| CHEMBL4107907 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4114159 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL4108338 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4107714 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4110311 | ↓ inhibits | Mechanistic | 9500.0 nM (IC50) | ChEMBL |
| CHEMBL4107559 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL4114106 | ↓ inhibits | Mechanistic | 1500.0 nM (IC50) | ChEMBL |
| CHEMBL4109097 | ↓ inhibits | Mechanistic | 11700.0 nM (IC50) | ChEMBL |
| CHEMBL4108330 | ↓ inhibits | Mechanistic | 2300.0 nM (IC50) | ChEMBL |
| CHEMBL4109114 | ↓ inhibits | Mechanistic | 4500.0 nM (IC50) | ChEMBL |
| CHEMBL3961039 | ↓ inhibits | Mechanistic | 7300.0 nM (IC50) | ChEMBL |
| CHEMBL4112247 | ↓ inhibits | Mechanistic | 10700.0 nM (IC50) | ChEMBL |
| CHEMBL4109308 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL4109014 | ↓ inhibits | Mechanistic | 11820.0 nM (IC50) | ChEMBL |
| CHEMBL4108567 | ↓ inhibits | Mechanistic | 3800.0 nM (IC50) | ChEMBL |
| CHEMBL4111131 | ↓ inhibits | Mechanistic | 18000.0 nM (IC50) | ChEMBL |
| CHEMBL4115372 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL4106481 | ↓ inhibits | Mechanistic | 3050.0 nM (IC50) | ChEMBL |
| CHEMBL4108186 | ↓ inhibits | Mechanistic | 5610.0 nM (IC50) | ChEMBL |
| CHEMBL4115360 | ↓ inhibits | Mechanistic | 5800.0 nM (IC50) | ChEMBL |
| CHEMBL4114503 | ↓ inhibits | Mechanistic | 25300.0 nM (IC50) | ChEMBL |
| CHEMBL4108540 | ↓ inhibits | Mechanistic | 2970.0 nM (IC50) | ChEMBL |
| CHEMBL4109409 | ↓ inhibits | Mechanistic | 5750.0 nM (IC50) | ChEMBL |
| CHEMBL4109932 | ↓ inhibits | Mechanistic | 14300.0 nM (IC50) | ChEMBL |
| CHEMBL4106569 | ↓ inhibits | Mechanistic | 16800.0 nM (IC50) | ChEMBL |
Showing top 40 of 170 agents ranked by evidence tier.
SERPINC1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TINZAPARIN SODIUM | ↑ activates | Mechanistic | DGIdb | |
| ELTROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| PROGESTERONE | ? unclear | Mechanistic | DGIdb | |
| FONDAPARINUX | ↑ activates | Mechanistic | DGIdb | |
| AVATROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ? unclear | Mechanistic | DGIdb | |
| NADROPARIN CALCIUM | ↑ activates | Mechanistic | DGIdb | |
| SULODEXIDE | ? unclear | Mechanistic | DGIdb | |
| MECAMYLAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]Α-BUNGAROTOXIN | ↓ inhibits | Mechanistic | DGIdb | |
| BEMIPARIN SODIUM | ↑ activates | Mechanistic | DGIdb | |
| ATRACURIUM | ↓ inhibits | Mechanistic | DGIdb | |
| LUSUTROMBOPAG | ? unclear | Mechanistic | DGIdb | |
| SEMULOPARIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| SYNTHETIC CONJUGATED ESTROGENS, A | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| HEPARIN | ↑ activates | Mechanistic | DGIdb | |
| ANTITHROMBIN ALFA | ? unclear | Mechanistic | DGIdb | |
| GEMCITABINE | ? unclear | Mechanistic | DGIdb | |
| DANAPAROID SODIUM | ↑ activates | Mechanistic | DGIdb | |
| GALLAMINE TRIETHIODIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PARNAPARIN SODIUM | ↑ activates | Mechanistic | DGIdb | |
| 2-O, 3-O DESULFATED HEPARIN | ? unclear | Mechanistic | DGIdb | |
| WAGLERIN-1 | ↓ inhibits | Mechanistic | DGIdb | |
| Α-CONOTOXIN GI | ↓ inhibits | Mechanistic | DGIdb | |
| DELPARANTAG | ? unclear | Mechanistic | DGIdb | |
| UNFRACTIONATED HEPARIN | ? unclear | Mechanistic | DGIdb | |
| [125I]Α-BUNGAROTOXIN | ↓ inhibits | Mechanistic | DGIdb | |
| Α-CONOTOXIN MI | ↓ inhibits | Mechanistic | DGIdb | |
| ENOXAPARIN SODIUM | ↑ activates | Mechanistic | DGIdb | |
| DOCIPARSTAT SODIUM | ? unclear | Mechanistic | DGIdb | |
| HEPARIN CALCIUM | ↑ activates | Mechanistic | DGIdb | |
| Α-BUNGAROTOXIN | ↓ inhibits | Mechanistic | DGIdb | |
| PANCURONIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ARDEPARIN SODIUM | ↑ activates | Mechanistic | DGIdb | |
| SUCCINYLCHOLINE | ↑ activates | Mechanistic | DGIdb | |
| HEPARIN SODIUM | ? unclear | Mechanistic | Open Targets | |
| DALTEPARIN SODIUM | ? unclear | Mechanistic | Open Targets | |
| FONDAPARINUX SODIUM | ? unclear | Mechanistic | Open Targets | |
| CHEMBL609990 | ↓ inhibits | Mechanistic | 58.0 nM (Kd) | ChEMBL |
Showing top 40 of 46 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon \[DCB\]) in the treatment of the femoropopliteal artery l...
This multicenter randomized controlled trial compare two transfusion strategies of red blood cells transfusion in patients supported by veno-arterial extracorporeal membrane oxygenation for refractory cardiogenic shock. An individualized transfusion strategy based on ScVO2 level, is compared to a c...
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin th...
This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure. The main question this study aims to answer is: \- Are temperature measurements from a forward looking infrared (FLIR) camera of the lower extremity use...
Chronic limb threatening ischemia (CLTI) represents the most advanced stage of peripheral arterial disease (PAD) and is characterized by ischemic rest pain, non-healing wounds, or ischemic gangrene. High-risk PAD populations including patients with end-stage renal disease and or diabetes also experi...
The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the ar...
TACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
A prospective pilot study examining nutritional supplements among vascular surgery patients with Critical Limb Ischemia (CLI). CLI patients have a high rate of malnutrition and has the potential to benefit greatly from nutritional intervention. The investigators plan to evaluate nutrition and functi...
Peripheral arterial disease involving the iliac arteries is a common manifestation of systemic atherosclerosis and a major cause of lifestyle-limiting claudication and chronic limb-threatening ischemia. Endovascular iliac artery stenting has become the preferred treatment strategy for most iliac les...
Non-randomized, multicenter, combined prospective and retrospective cohort analysis consisting of a single arm treated with the MicroStent™ System.
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®, but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.
This study will examine sleep disordered breathing and sleep quality in participants (ages 12-25) diagnosed with sickle cell disease of any genotype. We will utilize remote peripheral arterial tonometry (PAT) and questionnaires to evaluate difficulties with sleep. PAT assessments will occur remotely...
The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.
Peripheral arterial disease (PAD) is a chronic atherosclerotic condition associated with impaired mobility, reduced quality of life, cardiovascular events, and risk of lower limb amputation. Although supervised exercise therapy (SET) is recommended for symptomatic PAD, access and adherence remain li...
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain ne...
Searched directly from “Peripheral Artery Disease” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."